Today's Date: November 30, 2023
Technip Energies and John Cockerill Reach Closing of Rely, a New Company Dedicated to Integrated Green Hydrogen and Power-to-X S   •   SOUTH JERSEY TRANSPORTATION PLANNING ORGANIZATION HONORED FOR CUMBERLAND COUNTY PLAN TO PROTECT PEDESTRIANS AND CYCLISTS   •   The ODP Corporation to Present at the Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference Monday, D   •   Primerica Household Budget Index™: Middle-Income Households Saw Improving Financial Conditions in October   •   Zeta Marketing Platform Surges With 64% YoY Increase in Omnichannel Marketing During Holiday Season Kickoff   •   Seagrass, a global carbon marketplace and climate solutions company, launches in the United Arab Emirates   •   TEXAS DEPARTMENT OF TRANSPORTATION HONORED FOR REDUCING PEDESTRIAN FATALITIES ON AUSTIN'S I-35   •   SBB Research Group Foundation Names September 2023 Grant Finalists: In His Hands Resource Center, Milton Township Food Pantry, P   •   HelloGard Welcomes Sarah Hoit to Advisory Board   •   Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormon   •   Impact Podcast with John Shegerian to Feature Lineup of “ESG All-Stars” from Iconic Brands for December   •   Ecolomondo Releases Its Interim Consolidated Financial Statements for the Third Quarter of 2023. Provides Amendment to Market Ma   •   Sila Begins the Build-Out of its Moses Lake Plant for 2025 Production of Titan Silicon   •   FLORIDA DEPARTMENT OF TRANSPORTATION HONORED FOR FRICTION TREATMENT THAT REDUCES STOPPING DISTANCES AT INTERSECTIONS   •   CALTRANS HONORED FOR ENHANCING PEDESTRIAN SAFETY AND PREVENTING WRONG-WAY DRIVING AND RUN-OFF-ROAD CRASHES   •   Port Houston Second Annual Posada   •   IBM Advances Geospatial AI to Address Climate Challenges   •   LOUISIANA'S ACADIANA PLANNING COMMISSION HONORED FOR REDUCING SEVERE CRASHES AT RURAL "T" INTERSECTIONS   •   MINNESOTA DEPARTMENT OF TRANSPORTATION HONORED FOR WIDESPREAD USE OF "J-TURN INTERSECTIONS" TO REDUCE SEVERITY OF CRASHES   •   Oceaneering Announces Release of 2023 Task Force on Climate-Related Financial Disclosures Report
Bookmark and Share



PR Newswire

Dallas-area OB/GYN uses innovative REBOA catheter to manage hemorrhage during potential life-threatening deliveries

SAN ANTONIO, Oct. 2, 2023 /PRNewswire-PRWeb/ -- Prytime Medical Devices, Inc. is pleased to announce that Dr. Robert Cohen, Board-Certified Obstetrician-Gynecologist at Medical City Dallas, who specializes in women's reproductive health, particularly in cases involving placenta accreta spectrum (PAS), has recently performed his 100th PAS case, with the vast majority of them using Prytime Medical™ REBOA technology.

Being able to accurately measure central blood pressure is critical to making the most informed decisions for the mother and baby. Better control of the bleeding improves visibility of the operative field and minimizes blood loss.

The 100th case which occurred on Aug. 28, 2023, was a double celebration as twins were safely delivered via cesarean section.

Women in the US die from pregnancy and delivery complications at over twice the rate of women in other developed countries. The primary cause is peripartum hemorrhage, which is largely related to a dramatic rise in abnormal placentation. Further, placental blood loss during cesarean hysterectomy has the potential to exceed 700/ml/minute,1 and the danger is that many hospitals are unprepared to adequately manage hemorrhage in severe accreta cases.

"Most obstetricians may have only seen the rare case of placenta accreta and will not have seen the severe ends of that spectrum, nor be capable in treating it," said Dr. Cohen.

Dr. Cohen first realized the growing problem surrounding PAS about 10 years ago. Taking it as his mission to find a solution, Dr. Cohen researched ways to adequately control hemorrhage and discovered that traditional obstetrical methods such as uterine artery and common iliac artery balloon occlusion were inadequate. In December 2018, Cohen began using Prytime's ER-REBOA™ catheter as an adjunct for hemorrhage control in his PAS cases.

The REBOA catheter is a minimally invasive hemorrhage control device with the capability to significantly reduce blood loss and total blood transfusion in high-risk obstetrics. REBOA can be used for control in hemorrhagic instability and to significantly increase SBP with relatively few complications.2

In 2021, Dr. Cohen upgraded to Prytime's revolutionary pREBOA-PRO™ catheter. As the first catheter in the world designed for True Partial REBOA™, pREBOA-PRO™ partially occludes the aorta while providing two key capabilities:

  1. Core blood pressure monitoring of the aortic blood pressure for informed hemorrhage control
  2. More targeted, precise, and controlled distal perfusion of blood past the balloon

"Using pREBOA-PRO™ to control hemorrhage and manage blood loss gives a much more confident feeling going into these cases, especially the more extreme ones," said Dr. Cohen.

"Being able to accurately measure central blood pressure is critical to making the most informed decisions for the mother and baby. Better control of the bleeding improves visibility of the operative field and minimizes blood loss. If you can't see what you need to see, you will never control the source of the hemorrhage," said Dr. Cohen.

Dr. Cohen is one of the leading obstetricians experienced in treating severe PAS, and Medical City Dallas is one of the few medical centers in the world with access to the latest REBOA technology.

"At Prytime, we are driven by a mission that no one should bleed to death, and the sooner you stop the bleeding the better," said David Spencer, CEO Prytime Medical Devices, Inc. "The need to fulfill that mission is no more urgent than during childbirth," Spencer continued. "As we honor Accreta Awareness Month this October, we salute and celebrate Dr. Cohen's work in using REBOA as a tool to save these lives."

Both mother and twins have been discharged from the hospital and are at home doing well.

About Prytime Medical Devices, Inc.

Prytime Medical™ Devices, Inc. is an innovative medical device company that designs, develops, and commercializes minimally invasive solutions for hemorrhage control. The underlying intellectual property for REBOA was conceived based on lessons learned in war. Our latest innovations, the industry leading ER-REBOA PLUS™, and the innovative pREBOA-PRO™ Partial REBOA Catheter, enable truncal hemorrhage control with more controlled resuscitation in a much wider range of clinical scenarios. pREBOA-PRO™ is the first FDA-cleared REBOA catheter designed specifically for True Partial REBOA™. More information can be found at

1.    Palacios-Jaraquemada J M. Caesarean section in cases of placenta praevia and accreta. Best Pract Res Clin Obstet Gynaecol. 2013;27(02):221–32. doi: 10.1016/j.bpobgyn.2012.10.003.

2.    McGreevy, D. T., Sadeghi, M., Nilsson, K. F., & Hörer, T. M. (2021). Low profile REBOA device for increasing systolic blood pressure in hemodynamic instability: single-center 4-year experience of use of ER-REBOA. European Journal of Trauma and Emergency Surgery, 1-7.

Media Contact

Heather Salinas, Prytime Medical Devices, Inc., 210-340-0116,,


Cision View original content to download multimedia:

SOURCE Prytime Medical Devices, Inc.

Back to top
| Back to home page

White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News